Changing the Trajectory of Autoimmune Diseases
Aurinia Pharmaceuticals (auriniapharma.com) scores 78 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 65th percentile of 20064 Healthcare brands.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company founded in 2012 and headquartered in Edmonton, Canada, with operations also noted in Victoria, Canada. The company focuses on developing and delivering therapies for autoimmune diseases with high unmet medical needs, most notably lupus nephritis. Its flagship product, LUPKYNIS, is a targeted therapy designed for this condition. Aurinia serves patients, healthcare providers, caregivers, and investors interested in autoimmune disease treatment advancements, combining scientific innovation with patient support programs.
| Brand Name | Aurinia Pharmaceuticals |
|---|---|
| Domain | auriniapharma.com |
| Industry | Healthcare |
| Founded | 2012 |
| Headquarters | Edmonton |
| Main Competitors | GlaxoSmithKline (83/100), AstraZeneca (82/100), Bristol Myers Squibb (89/100), Genentech (84/100), UCB (89/100), Alexion Pharmaceuticals (87/100) |
Moz Domain Authority 44/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs." (Meta description: 22 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on X (Twitter), Instagram, GitHub; no detected presence on Facebook, LinkedIn, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Aurinia Pharmaceuticals?", Claude could identify the brand as of October 2026. Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, best known for its drug Lupkynis (voclosporin) used to treat lupus nephritis. Best known for Developing Lupkynis, the first oral therapy approved specifically for lupus nephritis.
When asked "Best brands similar to Aurinia Pharmaceuticals?", Claude would recommend Aurinia Pharmaceuticals as of October 2026. It would come up naturally in discussions of specialty pharma companies focused on autoimmune and kidney disease treatments.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Aurinia Pharmaceuticals's main competitors in Healthcare: GlaxoSmithKline (83/100), AstraZeneca (82/100), Bristol Myers Squibb (89/100), Genentech (84/100), UCB (89/100).
Sources: Brand Analyzer scan
Aurinia's primary product is LUPKYNIS, a targeted therapy for lupus nephritis. The company also offers patient-focused support programs to assist individuals using its therapies.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company founded in 2012, headquartered in Edmonton, Canada, that focuses on developing therapies for autoimmune diseases with high unmet medical needs.
Aurinia Pharmaceuticals has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 26, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Aurinia Pharmaceuticals was founded in 2012. Aurinia Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Aurinia Pharmaceuticals is headquartered in Edmonton. Aurinia Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Aurinia develops and delivers targeted therapies for autoimmune diseases, particularly lupus nephritis. Its key product, LUPKYNIS, is designed to address gaps in treatment options for this condition, and the company also provides patient-focused support programs alongside its drug development efforts.
Aurinia Pharmaceuticals scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Aurinia Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Aurinia Pharmaceuticals' therapies are used by patients living with autoimmune diseases, particularly lupus nephritis. The company also engages healthcare providers who prescribe and manage these treatments, caregivers supporting patients, and investors interested in autoimmune disease treatment advancements.
Aurinia Pharmaceuticals is known for developing LUPKYNIS, a targeted therapy for lupus nephritis, an autoimmune kidney condition with historically limited treatment options.
Aurinia Pharmaceuticals scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Aurinia Pharmaceuticals has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 44/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Aurinia Pharmaceuticals from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Aurinia Pharmaceuticals: Aulterra (78/100), Augmedix (78/100), Autism Ontario (78/100), Autism Society (78/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.